Managers / Q3 2020 · view latest →
Highlander Capital Management, LLC
CIK 0001519113 · 535 MILLBURN AVENUE, SHORT HILLS, NJ, 07078 · 973-718-3511
Summary
Highlander Capital Management, LLC reported $165M in U.S.-listed holdings across 638 positions for Q3 2020.
Its largest position, AAPL, represents 4.8% of the portfolio.
Compared with Q2 2020, the fund opened 68 new positions and exited 25.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 78.6% · $130M
- US DOMESTIC · 5.4% · $9M
- GLOBAL · 3.1% · $5M
- ETP · 2.6% · $4M
- Other · 2.6% · $4M
- Other · 7.7% · $13M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| INGRINGREDION INC | NEW | +14.5K | 14.5K | +$1M | $1M |
| AZNNASTRAZENECA PLC | NEW | +5.8K | 5.8K | +$318,000 | $318,000 |
| RGAREINSURANCE GROUP OF AMERICA | NEW | +1.8K | 1.8K | +$173,000 | $173,000 |
| INVESCO EXCHANGE-TRADED | NEW | +800 | 800 | +$86,000 | $86,000 |
| SEDGSOLAREDGE TECHNOLOGIES INC | NEW | +300 | 300 | +$72,000 | $72,000 |
| RXTRACKSPACE TECHNOLOGY INC | NEW | +3.0K | 3.0K | +$58,000 | $58,000 |
| BIIBBIOGEN INC | NEW | +200 | 200 | +$57,000 | $57,000 |
| TDOCTELADOC HEALTH INC | NEW | +250 | 250 | +$55,000 | $55,000 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2020
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2024 | $292M | 955 | May 20, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | Under review | 988 | Jan 24, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $254,445 | 958 | Nov 13, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $215,789 | 669 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $204,275 | 688 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | Under review | 657 | Feb 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $174M | 648 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $186M | 656 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $214M | 640 | May 9, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $216M | 621 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $197M | 619 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $200M | 635 | Aug 10, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $191M | 639 | May 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $179M | 643 | Feb 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $165M | 638 | Nov 17, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $159M | 595 | Aug 17, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $139M | 664 | May 27, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $174M | 625 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $162M | 658 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $165M | 717 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $162M | 722 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $152M | 695 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.